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Prostate-specific membrane antigen radioligand therapy
(PSMA-RLT) with 177Lu-PSMA holds great promise as a
safe treatment option in patients with metastasized
castration-resistant prostate cancer (mCRPC) with appro-
priate selection [1]. This approach, together with 68Ga-
PSMA PET/CT, is an excellent example of theranostic
nuclear medicine [2]. However, more structured data have
recently shown that despite a marked response to PSMA-
RLT, some patients are refractory to 177Lu-radioligand
therapy [2, 3]. Fortunately recent studies have demonstrat-
ed that targeted α-radiation therapy with 225Ac-PSMA can
significantly benefit mCRPC patients [4]. Similarly, 213Bi-
DOTATOC may be able to break the radioresistance to β-
emitters while simultaneously reducing haematological
toxicity in patients with diffuse red marrow infiltration
by neuroendocrine tumour [5].
We present the first-in-human treatment concept with
213Bi-PSMA-617 in a patient with mCRPC that was pro-
gressive under conventional therapy. The patient was
treated with two cycles of 213Bi-PSMA-617 with a cu-
mulative activity of 592 MBq. Restaging with 68Ga-
PSMA PET/CT after 11 months showed a remarkable
molecular imaging response. This pat ient a lso
demonstrated a biochemical response (decrease in PSA
level from 237 μg/L to 43 μg/L).
This case supports the need further exploration on the use
and supply of targeted α-radiation therapy.
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